NCT00475813已完成3 期
Study of FLUTIFORM® VS Seretide® in Paediatric Subjects With Asthma
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 211
- 试验地点
- 6
- 主要终点
- FEV1, recorded at visits to investigator at 2 wks, 6wks & 12 wks.
研究概览
简要总结
Study compares the efficacy and safety of FLUTIFORM® with Seretide® in the treatment of mild to moderate persistent asthma in pediatric subjects.
详细描述
This is a study involving a 12 week treatment phase followed by a 6 month extension phase. During the treatment phase subjects receive FLUTIFORM® or Seretide®. In the extension phase all subjects receive FLUTIFORM®. Efficacy will be assessed by lung function tests and asthma symptoms, sleep disturbance. Safety will be assessed by adverse events, vital signs, lab tests and ECGs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- None
入排标准
- 年龄范围
- 4 Years 至 12 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients between 4-12 years of age. Female patients must be pre-menarche to be eligible.
- •Known history of mild to moderate reversible asthma for ≥ 6 months prior to the screening visit.
- •Demonstrate a FEV1 of ≥60% to ≤80% of predicted normal values (Zapletal, 1977) during the screening phase following appropriate withholding of asthma medications (if applicable).
- •No beta agonist use on day of screening.
- •No use of combination asthma therapy on day of screening.
- •Inhaled corticosteroids are allowed on day of screening.
- •Documented reversibility of ≥ 15% in FEV1 during the screening phase.
- •Demonstrate satisfactory technique in the use of the pressurized MDI and spacer device.
- •Willing and able to enter information in the electronic diary (parental help is acceptable for young children) and attend all study visits.
- •Willing and able to substitute study medication for their pre study prescribed asthma medication for the duration of the study.
- •Written informed parental consent obtained, and where possible informed assent from the patient.
排除标准
- •Life-threatening asthma within the past year. This category includes those patients with a history of near-fatal asthma, a hospitalization or an emergency visit for asthma or prior intubation for asthma.
- •History of systemic (injectable) corticosteroid medication within 1 month before the Screening Visit.
- •History of leukotriene receptor antagonist use, e.g. montelukast, within the past week.
- •Current evidence or history of any clinically significant disease or abnormality including uncontrolled coronary artery disease, congestive heart failure, or cardiac dysrhythmia. 'Clinically significant' is defined as any disease that, in the opinion of the Investigator, would put the patient at risk through study participation, or which would affect the outcome of the study.
- •An upper or lower respiratory infection within 4 weeks prior to the Screening Visit.
- •Significant, non-reversible, active pulmonary disease (e.g., chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, tuberculosis).
- •Known Human Immunodeficiency Virus (HIV)-positive status.
- •Current smoking history within 12 months prior to the Screening Visit.
- •Current evidence or history of alcohol and/or substance abuse within 12 months prior to the Screening Visit.
- •Patients who have taken B-blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole (Hismanal), quinidine type antiarrhythmics, or potent CYP 3A4 inhibitors such as ketoconazole within the past week.
- •Current use of medications that will have an effect on bronchospasm and/or pulmonary function.
- •Current evidence or history of hypersensitivity or idiosyncratic reaction to test medications or components.
- •Receipt of an investigational drug within 30 days of the Screening Visit (12 weeks if an oral or injectable steroid).
- •Current participation in a clinical study.
结局指标
主要结局
FEV1, recorded at visits to investigator at 2 wks, 6wks & 12 wks.
次要结局
- Lung function tests, peak expiratory flow rate, asthma symptoms & exacerbations, adverse events, sleep disturbance, rescue medication use, plasma cortisol (extension only).
研究者
研究点 (6)
Loading locations...
相似试验
已完成
3 期
Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible AsthmaAsthmaNCT01099722Mundipharma Research Limited261
已完成
3 期
Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe AsthmaAsthma, BronchialNCT00734318Mundipharma Research Limited1,667
已完成
3 期
An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible AsthmaAsthma BronchialeNCT00563056Mundipharma Research Limited227
已完成
3 期
Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric PatientsAsthmaNCT01511367Mundipharma Research Limited498
已完成
2 期
Flutiform® Compared With Seretide® in the Treatment of COPDChronic Obstructive Pulmonary DiseaseNCT02195375Mundipharma Research Limited923